Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6832)
All Articles published online
|
Publishing Process of This Article
|
Oct 10, 2015 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Petrioli R, Francini E, Roviello G. Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 2015; 6(5): 99-103 [PMID: 26468445 DOI: 10.5306/wjco.v6.i5.99] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i5/99.htm |
| Number | Citing Articles |
| 1 |
Ajit Venniyoor, Itrat Mehdi, Rajan Balakrishnan, Bassim Al Bahrani. Early Chemotherapy in Metastatic Prostate Cancer Improves Survival: a Quick Note to Surgical Colleagues. Indian Journal of Surgery 2020; 82(6): 1206 doi: 10.1007/s12262-020-02213-y
|
| 2 |
Agnieszka Maj-Hes, Tibor Szarvas, Sabina Sevcenco, Gero Kramer. Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. Advances in Therapy 2021; 38(7): 3831 doi: 10.1007/s12325-021-01778-8
|
| 3 |
Giandomenico Roviello, Navid Sobhani, Silvia Paola Corona, Alberto D’Angelo. Corticosteroid switch after progression on abiraterone acetate plus prednisone. International Journal of Clinical Oncology 2020; 25(2): 240 doi: 10.1007/s10147-019-01577-w
|
| 4 |
Renliang Yi, Baoxin Chen, Peng Duan, Chanjiao Zheng, Huanyu Shen, Qun Liu, Chen Yuan, Weilin Ou, Zhiheng Zhou. Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis. Journal of Immunology Research 2016; 2016: 1 doi: 10.1155/2016/4543861
|
| 5 |
Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Vito Cucchiara, Xinwei Gu, Wei Lou, Christopher P. Evans, Allen C. Gao. ABCB1 Mediates Cabazitaxel–Docetaxel Cross-Resistance in Advanced Prostate Cancer. Molecular Cancer Therapeutics 2017; 16(10): 2257 doi: 10.1158/1535-7163.MCT-17-0179
|
| 6 |
P. V. Mazin, N. K. Mazina. Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data. Cancer Urology 2018; 13(4): 91 doi: 10.17650/1726-9776-2017-13-4-91-100
|
| 7 |
Giandomenico Roviello, Benedetta Panella. How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancer. Reports of Practical Oncology & Radiotherapy 2020; 25(4): 701 doi: 10.1016/j.rpor.2020.04.009
|
| 8 |
Giandomenico Roviello, Silvia Paola Corona, Raffaele Conca, Roberto Petrioli, Pietro Rosellini, Alberto Bonetta, Michele Aieta. Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. Medicine 2019; 98(26): e16249 doi: 10.1097/MD.0000000000016249
|
| 9 |
Giandomenico Roviello, Sandra Sigala, Shahneen Sandhu, Alberto Bonetta, Maria Rosa Cappelletti, Laura Zanotti, Alberto Bottini, Cora N. Sternberg, Stephen B. Fox, Daniele Generali. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer 2016; 61: 111 doi: 10.1016/j.ejca.2016.04.002
|
| 10 |
Maria Picciotto, Tindara Franchina, Alessandro Russo, Giuseppina Rosaria Rita Ricciardi, Giusy Provazza, Serena Sava, Sergio Baldari, Orazio Caffo, Vincenzo Adamo. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy 2017; 18(9): 899 doi: 10.1080/14656566.2017.1323875
|
| 11 |
Mohamed H Kamel, Omer A Raheem, Rodney Davis. New horizons in the management of castrate-resistant prostate cancer. Journal of Clinical Urology 2018; 11(4): 258 doi: 10.1177/2051415817731397
|
| 12 |
Giandomenico Roviello, Maria Rosa Cappelletti, Laura Zanotti, Angela Gobbi, Chiara Senti, Alberto Bottini, Andrea Ravelli, Alberto Bonetta, Giovanni Paganini, Daniele Generali. Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer. Medicine 2016; 95(43): e4636 doi: 10.1097/MD.0000000000004636
|
| 13 |
G. Roviello, M. R. Gatta Michelet, A. D’Angelo, S. Nobili, E. Mini. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. Clinical and Translational Oncology 2020; 22(7): 1033 doi: 10.1007/s12094-019-02228-2
|
| 14 |
Dalin He, Zhongquan Sun, Jianming Guo, Zhigen Zhang, Yuxi Shan, Lulin Ma, Hanzhong Li, Jie Jin, Yiran Huang, Jiaquan Xiao, Qiang Wei, Dingwei Ye. A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China. Asia-Pacific Journal of Clinical Oncology 2019; 15(3): 144 doi: 10.1111/ajco.13142
|
| 15 |
Xing-Hui Wang, Zhi-Qiang Wang, Zhen-Yu Mu, Li-Ping Zhu, Chong-Fu Zhong, Shanchun Guo. The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Medicine 2022; 101(31): e29715 doi: 10.1097/MD.0000000000029715
|